Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1980 Oct;35(10):788–791. doi: 10.1136/thx.35.10.788

Evidence that rifampicin can be used safely for non-tuberculous diseases.

G Acocella, W Brumfitt, J M Hamilton-Miller
PMCID: PMC471381  PMID: 6781092

Abstract

The incidence of primary resistance to rifampicin in Mycobacterium tuberculosis has been analysed in countries where rifampicin is restricted to use for treating tuberculosis and in countries where its use is not restricted. There is no evidence that rifampicin-resistant M tuberculosis strains are more common where the use of the drug is unrestricted. Resistance to rifampicin is less common than is resistance to streptomycin or to isoniazid. We can thus see no danger of producing resistant strains of M tuberculosis if rifampicin therapy is used for short periods for non-tuberculosis infections. The problem of resistance mutants arising in the non-tuberculous species being treated is overcome by combining rifampicin with trimethoprim.

Full text

PDF
788

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Acocella G., Hamilton-Miller J. M., Brumfitt W. Can rifampicin use be safely extended? Evidence for non-emergence of resistant strains of Mycobacterium tuberculosis. Lancet. 1977 Apr 2;1(8014):740–742. doi: 10.1016/s0140-6736(77)92179-1. [DOI] [PubMed] [Google Scholar]
  2. Acocella G., Scotti R. Kinetic studies on the combination rifampicin-trimethoprim in man. I. Absorption and urinary excretion after administration to healthy volunteers of single doses of the two compounds alone and in combination, and of the combination over a period of 1 week. J Antimicrob Chemother. 1976 Sep;2(3):271–277. doi: 10.1093/jac/2.3.271. [DOI] [PubMed] [Google Scholar]
  3. Amadio G. E. Evolucion de los indices de resistencia bacteriana en tuberculosis en la republica Argentina. Arch Monaldi. 1977 Jan-Apr;32(1-2):12–28. [PubMed] [Google Scholar]
  4. Arioli V., Berti M., Carniti G., Rossi E. Interaction between rifampicin and trimethoprim in vitro and in experimental infections. J Antimicrob Chemother. 1977 Jan;3(1):87–94. doi: 10.1093/jac/3.1.87. [DOI] [PubMed] [Google Scholar]
  5. Atlas E., Turck M. Laboratory and clinical evaluation of rifampicin. Am J Med Sci. 1968 Oct;256(4):47–54. [PubMed] [Google Scholar]
  6. Binda G., Domenichini E., Gottardi A., Orlandi B., Ortelli E., Pacini B., Fowst G. Rifampicin, a general review. Arzneimittelforschung. 1971 Dec;21(12):1907–1977. [PubMed] [Google Scholar]
  7. Briccarello L., Bardessono F., Daglio C., Ferraro U., Giorgis G. E., Moschini M. T. Il fenomeno della resistenza primaria del bacillo di Koch: casistica raccolta nell'ospedale pneumologico S. Luigi di Torino dal 1972 al 1975. G Batteriol Virol Immunol. 1976 Jan-Jun;69(1-6):49–59. [PubMed] [Google Scholar]
  8. Canetti G., Fox W., Khomenko A., Mahler H. T., Menon N. K., Mitchison D. A., Rist N., Smelev N. A. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ. 1969;41(1):21–43. [PMC free article] [PubMed] [Google Scholar]
  9. Citron K. M., May J. R. Rifamycin antibiotics in chronic purulent bronchitis. Lancet. 1969 Nov 8;2(7628):982–983. doi: 10.1016/s0140-6736(69)90539-x. [DOI] [PubMed] [Google Scholar]
  10. Hamilton-Miller J. M., Brumfitt W. Trimethoprim and rifampicin: pharmacokinetic studies in man. J Antimicrob Chemother. 1976 Jun;2(2):181–188. doi: 10.1093/jac/2.2.181. [DOI] [PubMed] [Google Scholar]
  11. Kerry D. W., Hamilton-Miller J. M., Brumfitt W. Trimethoprim and rifampicin: in vitro activities separately and in combination. J Antimicrob Chemother. 1975 Dec;1(4):417–427. doi: 10.1093/jac/1.4.417. [DOI] [PubMed] [Google Scholar]
  12. Kopanoff D. E., Kilburn J. O., Glassroth J. L., Snider D. E., Jr, Farer L. S., Good R. C. A continuing survey of tuberculosis primary drug resistance in the United States: March 1975 to November 1977. A United States Public Health Service cooperative study. Am Rev Respir Dis. 1978 Nov;118(5):835–842. doi: 10.1164/arrd.1978.118.5.835. [DOI] [PubMed] [Google Scholar]
  13. Murdoch J. M., Speirs C. F., Wright N., Wallace E. T. Rifampicin. Lancet. 1969 May 31;1(7605):1094–1094. doi: 10.1016/s0140-6736(69)91725-5. [DOI] [PubMed] [Google Scholar]
  14. Nitti V. La resistenza primaria del micobatterio tubercolare. Aspetti batteriologici ed epidemiologici. Arch Monaldi. 1972 Jul-Aug;27(4):454–474. [PubMed] [Google Scholar]
  15. Ortega Calderon A., March Arbos J. Evolucion de la resistencia primaria del mycobacterium tuberculosis en los ultimos 5 años (1970-1976). Arch Monaldi. 1977 Jan-Apr;32(1-2):3–11. [PubMed] [Google Scholar]
  16. Pien F. D., Michael N. L., Ow C. L., Vennesland K., Brodsky M. L. Primary antituberculous drug resistance in Hawaii, 1957 to 1977. Am Rev Respir Dis. 1978 Oct;118(4):701–704. doi: 10.1164/arrd.1978.118.4.701. [DOI] [PubMed] [Google Scholar]
  17. Simmons N. A. Synergy and rifampicin. J Antimicrob Chemother. 1977 Mar;3(2):109–111. doi: 10.1093/jac/3.2.109. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES